Snipd home pageGet the app
public
The Readout Loud chevron_right

244: Pharma blockbusters, pandemic policy, & legal chicanery

Feb 2, 2023
35:29
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
1
Introduction
00:00 • 2min
chevron_right
2
The New Class of Drugs to Treat Diabetes and Obesity
01:40 • 3min
chevron_right
3
Diabetes Drugs
04:31 • 2min
chevron_right
4
Is There a Clinical Trial of GLP1?
06:03 • 3min
chevron_right
5
Big Pharma Earnings - What Did You Hear?
08:35 • 3min
chevron_right
6
Pfizer's COVID-19 Vaccines - Is China a Boon to Western Drug Companies?
11:55 • 3min
chevron_right
7
What's Going on With Novavax?
14:36 • 4min
chevron_right
8
The Texas Two Step
18:30 • 3min
chevron_right
9
Covid-19
21:42 • 2min
chevron_right
10
The White House's Decision to End the Public Health Emergency
23:15 • 2min
chevron_right
11
What Does This Mean for Medicaid?
25:03 • 3min
chevron_right
12
What Does the End of the Emergency Declaration Mean for COVID?
27:55 • 2min
chevron_right
13
Is There a Transition Period?
30:15 • 2min
chevron_right
14
COVID - Is This the End?
32:19 • 3min
chevron_right
STAT Washington correspondent Rachel Cohrs joins us to explain the looming end of Covid-19's status as a federal emergency and what that does and doesn't mean for public health. We also dig into the most interesting stories from a busy week of pharmaceutical earnings and discuss a legal setback for Johnson & Johnson.
HomeTop podcastsPopular guestsTop books